High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis
- 1 September 1994
- journal article
- clinical trial
- Published by Elsevier in Thrombosis Research
- Vol. 75 (5) , 513-520
- https://doi.org/10.1016/0049-3848(94)90226-7
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disordersAnnals of Hematology, 1991
- Circulating activated platelets in myeloproliferative disordersThrombosis Research, 1991
- Induction of plasminogen activator inhibitor by products released from platelets.Circulation, 1990
- Platelet function in myeloproliferative disorders: Characterization and sequential studies show multiple platelet abnormalities, and change with timeEuropean Journal of Haematology, 1988
- Comparison of plasminogen activator inhibitor activity and antigen in plasma samplesClinica Chimica Acta; International Journal of Clinical Chemistry, 1987
- Quantitation of tissue-type plasminogen activator in human endothelial cell cultures by use of an enzyme immunoassayThrombosis Research, 1984
- Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: Relationship to platelet number and functionEuropean Journal of Cancer and Clinical Oncology, 1983
- An immunoassay for human D dimer using monoclonal antibodiesThrombosis Research, 1983
- Evidence for a rapid inhibitor to tissue plasminogen activator in plasmaThrombosis Research, 1983
- Antithrombin (heparin cofactor) assay with “new” chromogenic substrates (S-2238 and Chromozym TH)Thrombosis Research, 1977